Anticardiolipin antibodies and the risk of recurrent thrombo-occlusive events and death

Neurology

Volumn 48, Issue 1, 1997, Pages 91-94

  Stern, B J ^a  

^a EMORY UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOLIPIN ANTIBODY;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DEATH; DEEP VEIN THROMBOSIS; FEMALE; HEART INFARCTION; HUMAN; MALE; PATHOGENESIS; PRIORITY JOURNAL; STROKE; THROMBOSIS; TRANSIENT ISCHEMIC ATTACK;

EID: 0343567810     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.48.1.91     Document Type: Article

References (13)

1. The Antiphospholipid Antibodies in Stroke Study (APASS) Group. Anticardiolipin antibodies are an independent risk factor for first ischemic stroke. Neurology 1993;43:2069-2073.
2. Sletnes KE, Smith P, Abdelnoor M, Arnesen H, Wisloff F. Antiphospholipid antibodies after myocardial infarction and their relation to mortality, reinfarction, and non-haemorrhagic stroke. Lancet 1992;339:451-453.
3. Manoussakis MN, Tzioufas AG, Silis MP, Pange PJE, Goudevenos J, Moutsopoulos HM. High prevalence of anticardiolipin and other autoantibodies in a healthy elderly population. Clin Exp Immunol 1987;69:557-565.
4. Levine SR, Brey RL, Sawaya KL, et al. Recurrent stroke and thrombo-occlusive events in the antiphospholipid syndrome. Ann Neurol 1995;38:119-124.
5. Burn J, Dennis M, Bamford J, Sandercock P, Wade D, Warlow C. Long-term risk of recurrent stroke after a first-ever stroke. The Oxfordshire Community Stroke Project. Stroke 1994;25: 333-337.
6. Lai SM, Alter M, Friday G, Sobel E. A multifactorial analysis of risk factors for recurrence of ischemic stroke. Stroke 1994; 25:958-962.
7. Levine SR, Deegan MJ, Futrell N, Welch KMA. Cerebrovascular and neurologic disease associated with antiphospholipid antibodies: 48 cases. Neurology 1990;40:1181-1189.
8. Rosove MH, Brewer PMC. Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients. Ann Intern Med 1992;117:303-308.
9. Tohgi H, Takahashi H, Kashiwaya M, Watanabe K, Hayama K. The anticardiolipin antibody in elderly stroke patients: its effects on stroke types, recurrence, and the coagulation-fibrinolysis system. Acta Neurol Scand 1994;90:86-90.
10. Montalban J, Rio J, Khamastha M, et al. Value of immunologic testing in stroke patients. A prospective multicenter study. Stroke 1994;25:2412-2415.
11. Muir KW, Squire IB, Alwan W, Lees KR. Anticardiolipin antibodies in an unselected stroke population. Lancet 1994;344: 452-456.
12. Feldmann E, Levine SR. Cerebrovascular disease with antiphospholipid antibodies. Immune mechanisms, significance and therapeutic options. Ann Neurol 1995;37(suppl 1):S114-S130.
13. The WARSS, APASS, PICSS, and HAS Study Groups. The feasibility of a collaborative double-blind study using an anticoagulant: the Warfarin-Aspirin Recurrent Stroke Study (WARSS), the Antiphospholipid Antibodies and Stroke Study (APASS), the Patent Foramen Ovale in Cryptogenic Stroke Study (PICSS), and the Hemostatic System Activation Study (HAS). Cerebrovasc Dis (in press).